Arthritis,Rheumatoid
Conditions
Brief summary
We can speculate that the best responders to tocilizumab should have multiple related elements (Treg CD39, adenosine, IL-35) successfully induced and expressed in order to play its beneficial role. The study of these elements and its pathways could help identify the best responders to tocilizumab treatment.
Interventions
DRUGTocilizumab
DRUGAdalimumab
Sponsors
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients of all sexes, aged ≥ 18 years. * RA Patients (according to ACR / EULAR criteria 2010) of moderate to severe activity (DAS 28\> 3.2 or SDAI\> 11), and 6 months or more of evolution, starting treatment with ACTEMRA (tocilizumab) or with an anti-TNF, according to the product data. * Patients with body weight ≤ 150 kg. * Patients who have received written information about the study and gave their informed consent to participate in the study
Exclusion criteria
* Patients with a history of autoimmune disease or inflammatory joint disease other than RA. * Patients treated with any investigational agent within 4 weeks (or 5 half-lives of investigational agent, whichever is greater) before starting treatment with tocilizumab
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treg phenotype | Baseline to 6 months change |
| ATP (adenosine triphosphate) | Baseline to 6 months change |
Countries
Spain
Outcome results
None listed